Certara stock analysis
Certara (700) Stock Price & Analysis
700 Stock Chart & Stats
- Day’s Range
- EUR 10.54 - EUR 10.65
- 52-Week Range
- EUR 3.74 - EUR 10.92
- Previous Close
- EUR 10.32
- Volume
- N/A
- Average Volume (3M)
- 53
- Market Cap
- EUR 1.60B
- Enterprise Value
- EUR 1.49B
- Total Cash (Recent Filing)
- EUR 214.93M
- Total Debt (Recent Filing)
- EUR 298.23M
- Price to Earnings (P/E)
- ―
- Beta
- 1.13
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Software Growth And Bookings
Double-digit software growth and stronger bookings indicate improving demand for Certara’s core platforms. With software exceeding half of revenue, continued adoption can increase recurring revenue exposure, deepen customer relationships, and support more durable growth than project-based activity alone.
Resilient Cash Generation
Positive operating and free cash flow provide internal funding for product investment, cloud adoption, and debt or operating needs even while reported earnings remain negative. This cash generation gives Certara greater flexibility to execute its strategy without relying entirely on external capital.
Margin Expansion And Cost Savings
Improving adjusted EBITDA margins alongside realized cost savings suggests operating actions are producing measurable efficiency benefits. If maintained, stronger contribution margins can offset slower revenue growth, improve cash conversion over time, and increase the earnings power of the existing software portfolio.
Bears Say
Persistent Net Losses
Continued net losses show that Certara has not yet translated its gross margin and adjusted EBITDA performance into consistent bottom-line profitability. Ongoing losses can constrain capital allocation, weaken returns on equity, and leave the business more dependent on operational improvements to sustain long-term value creation.
Soft Services Growth And Slower Outlook
Weakness in services revenue and bookings limits near-term growth while the narrower company-wide outlook signals reduced momentum. Because services remain a major revenue stream, execution improvements must convert into sustained demand before Certara can achieve broader, more consistent growth across the business.
Cloud Conversion Revenue Headwind
The shift to cloud may improve bookings and strengthen the product model over time, but ratable recognition temporarily suppresses reported revenue during the transition. This creates a multi-quarter pressure on growth comparisons and makes execution important while customers migrate to the new platform.
Certara News
700 FAQ
What was Certara’s price range in the past 12 months?
What is Certara’s market cap?
When is Certara’s upcoming earnings report date?
How were Certara’s earnings last quarter?
Is Certara overvalued?
Does Certara pay dividends?
What is Certara’s EPS estimate?
How many shares outstanding does Certara have?
What happened to Certara’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Certara?
What is the TipRanks Smart Score and how is it calculated?
Certara Stock Smart Score
Company Description
Certara
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Jon Resnick
- Employees
- 1,546
- Website
- www.certara.com
- Address
- 4 Radnor Corporate Center, Radnor, PA, 19087, US
Certara (700) Earnings & Revenues
700 Company Deck
700 Earnings Call
Earnings Call SentimentPositive
The call was generally positive. Software growth, bookings, adjusted EBITDA expansion, cost savings, AI initiatives, cloud adoption, regulatory contracts, and commercial restructuring represented significant positives. These were partly offset by declining services revenue and bookings, the narrowed 2026 revenue growth outlook, a continuing operations net loss, restructuring costs, tax expense, and the revenue headwind from cloud conversion. Highlights significantly outweighed the lowlights.
View all DE:700 earnings summaries700 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 10 | 0 | 2 |
